← Back to Search

Neuromodulation

Neuromodulation for Obsessive-Compulsive Disorder

N/A
Waitlist Available
Research Sponsored by Boston University Charles River Campus
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 months after intervention
Awards & highlights

Study Summary

This trial is researching a new method to reduce OCD symptoms, with minimal side effects, using brain wave recordings to repetitively modulate an area of the brain affected by OCD.

Who is the study for?
This trial is for adults with OCD who score at least 16 on the YBOCS, can consent to participate, and follow study rules. It's not for those with severe depression, pregnancy, metal head implants, electronic devices in body, vision issues despite correction, claustrophobia or neurological disorders like epilepsy.Check my eligibility
What is being tested?
The study tests a new non-invasive neuromodulation technique using HD-tACS guided by EEG to reduce OCD symptoms quickly (within five days) and sustainably (up to three months). The focus is on modulating brain rhythms in the OFC that are linked with reward and decision-making.See study design
What are the potential side effects?
Since this method is non-invasive and well-tolerated based on preliminary data, minimal side effects are expected. However, specific side effects aren't detailed here; they may include discomfort from wearing stimulation equipment or mild headaches.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 months after intervention
This trial's timeline: 3 weeks for screening, Varies for treatment, and 3 months after intervention for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Secondary outcome measures
EEG beta-gamma rhythms
YBOCS

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: Active HD-tACSActive Control1 Intervention
HD-tACS of OFC
Group II: Sham HD-tACSPlacebo Group1 Intervention
HD-tACS of OFC

Find a Location

Who is running the clinical trial?

Boston University Charles River CampusLead Sponsor
114 Previous Clinical Trials
12,200 Total Patients Enrolled
2 Trials studying Obsessive-Compulsive Disorder
100 Patients Enrolled for Obsessive-Compulsive Disorder

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Could patients currently enroll in this research endeavor?

"According to clinicaltrials.gov, the last update for this trial was made on October 13th 2023 and it is not actively recruiting at present. However, there are 23 other medical studies that are presently looking for participants."

Answered by AI
Recent research and studies
clinicaltrials.govStudy
Neuromodulation for a Novel OCD Biomarker and Treatment
Robert Reinhart 2023. "Neuromodulation for a Novel OCD Biomarker and Treatment". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05994053.
All > Ocd
~60 spots leftby Aug 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top